Therefore, new non-hematopoietic EPO analogues may be of potential benefit, since they possess the pleiotropic effects of EPO without increasing the production of blood cells [32], [33] and therefore potentially may help patients with recurrent hypoglycemia to avoid these undesirable and potentially dangerous episodes. The gene discussed is EPO; the disease is Hypoglycemia.